ATV 1601
Alternative Names: ATV-1601Latest Information Update: 10 Aug 2026
At a glance
- Originator Atavistik Bio
- Class Antineoplastics; Small molecules; Vascular disorder therapies
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hereditary haemorrhagic telangiectasia
- Phase I HER2 negative breast cancer; Solid tumours
Most Recent Events
- 30 Jul 2026 Phase-I/II clinical trials in Hereditary haemorrhagic telangiectasia in USA (PO) (NCT07601425)
- 09 Jun 2026 ATV 1601 receives Fast Track designation for Hereditary haemorrhagic telangiectasia [PO,Capsule] in USA
- 09 Jun 2026 Pharmacodynamics data from a preclinical trial in Hereditary haemorrhagic telangiectasia released by Atavistik Bio